Welcome to EXIR PHARMACEUTICAL CO. WebSite
|
» NEWS
AND EVENTS |
|
|
|
The gathering was held from 24th August 2008 till 26th August in Tehran...
|
|
|
Welcome to EXIR PHARMACEUTICAL CO. WebSite
|
»
ARTICLE OF THE DAY |
|
|
|
Comparison of two treatment regimens in symptomaticaliy homogenous gerd patient
Populations : pantoprazole relieves gastrointestinal symptoms significantily better than omeprazole
|
|
|
|
Welcome to EXIR PHARMACEUTICAL CO. WebSite
|
»
EXIR PRODUCTS IN A GLANCE |
|
|
|
|
|
Welcome to EXIR PHARMACEUTICAL CO. WebSite
|
|
»
EXIR PRODUCTS
|
|
|
|
|
| |
|
|
|
Ofloxacin - Exir |
|
|
|
|
Generic Name: |
|
|
Ofloxacin |
|
|
Dosage: |
|
|
200 mg F.C . Tab/100 s |
|
|
A primary bacterial target of Loflox® is the enzyme DNA
gyrase, that contains four subunits, two “A” and two “ B”
subunits. Genetic and biochemical studies have identified the
A subunit of DNA gyrase ( type II topoisomerase) as the
target of Loflox®. Loflox® inhibits all the enzymatic activities
of DNA gyrase , including inhibition of negative supercoiling,
the joining and separation of interlocked DNA circles.
Loflox® has bactericidal activity against sensitive bacteria.
|
|
|
|
|
|
Ofloxacin - Exir |
|
|
|
|
Generic Name: |
|
|
Ofloxacin |
|
|
Dosage: |
|
|
300 mg F.C.Tab /20 s |
|
|
A primary bacterial target of Loflox® is the enzyme DNA
gyrase, that contains four subunits, two “A” and two “ B”
subunits. Genetic and biochemical studies have identified the
A subunit of DNA gyrase ( type II topoisomerase) as the
target of Loflox®. Loflox® inhibits all the enzymatic activities
of DNA gyrase , including inhibition of negative supercoiling,
the joining and separation of interlocked DNA circles.
Loflox® has bactericidal activity against sensitive bacteria.
|
|
|
|
|
|
|
|
|
|
|
|
Fluoxetine - Exir |
|
|
|
|
Generic Name: |
|
|
Fluoxetine |
|
|
Dosage: |
|
|
20 mg Cap/100 s |
|
|
Lorazac® and its major active metabolite, norfluoxetine, are
potent and selective inhibitors of 5-HT (5-hydroxytryptamine)
uptake.
Lorazac® is given as a racemate so two enantiomers are
present, both of which have similar activity, at least in terms
of 5-HT uptake inhibition.
Chronic administration of Lorazac® to rats leads to a decrease
in the density of 5-HT binding sites in cerebral cortex.
Moreover, it reduces the turnover of 5-HT in the CNS, an
effect reflected in the reduction of the major metabolite of 5-
HT, 5-HIAA (5-hydroxyindoleacetic acid). Lorazac® reduces
serotonin transporter mRNA levels but only transiently.
|
|
|
|
|
|
|
|
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
|
|
|
|
|
|
|
